News FDA to decide on Takeda's psoriasis blockbuster hope in Q1 The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.
News Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.
News Takeda plans filings for Sotyktu rival on new psoriasis data Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.
News AI specialists Enveda and Basecamp rake in the cash AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.